metformin has been researched along with warfarin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Burhans, R; Butte, AJ; Chen, R; Davuluri, RV; Gupta, R; Kim, HL; Miller, W; Rajesh, C; Ratan, A; Santhosh, S; Schuster, SC; Seshagiri, S; Thomas, G | 1 |
| Brøsen, K; Christensen, MM; Damkier, P; Henriksen, DP; Højlund, K; Pottegård, A; Stage, TB | 1 |
| Groen-Wijnberg, M; Kerbusch, V; Krauwinkel, W; Meijer, J; Tretter, R; van Dijk, J; van Gelderen, M; Zhang, W | 1 |
| Abdallah, K; Hamilton, RJ; Joshua, AM; Khoja, L; Pintilie, M; Pitcher, B | 1 |
| Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD | 1 |
| Brand, K; D'Haese, PC; De Broe, ME; De Maré, A; Gottwald-Hostalek, U; Kamel, S; Lalau, JD; Neven, E; Opdebeeck, B; Verhulst, A; Vervaet, B | 1 |
| Bilker, WB; Brensinger, CM; Han, X; Hennessy, S; Leonard, CE; Nam, YH | 2 |
| Anderson, TW; Borregaard, J; Bækdal, TA; Hansen, CW; Thomsen, M | 1 |
| Bian, J; El-Omar, E; Gong, L; Han, L; Li, K; Liu, H; Wang, M; Xiao, Y; Zhai, X | 1 |
| Donnelly, L; Dunvald, AD; Ernst, MT; Højlund, K; Kristiansen, MR; Madsen, JS; Nielsen, F; Nielsen, JS; Olsen, DA; Pearson, E; Persson, F; Pottegård, A; Soto-Pedre, E; Stage, TB; Søndergaard, J | 1 |
1 review(s) available for metformin and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for metformin and warfarin
| Article | Year |
|---|---|
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Topics: Adolescent; Adult; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Warfarin; Young Adult | 2017 |
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Caprylates; Cardiotonic Agents; Case-Control Studies; Cross-Over Studies; Digoxin; Drug Interactions; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Lisinopril; Male; Metformin; Middle Aged; Warfarin | 2019 |
22 other study(ies) available for metformin and warfarin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Sequencing and analysis of a South Asian-Indian personal genome.
Topics: Anticoagulants; Asian People; Chromosome Mapping; Diabetes Mellitus; DNA Copy Number Variations; Female; Genetic Predisposition to Disease; Genetic Variation; Genome, Human; Genome, Mitochondrial; Haplotypes; Hemorrhage; Humans; Hypoglycemic Agents; India; Metformin; Middle Aged; Multiple Sclerosis; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Warfarin | 2012 |
Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.
Topics: Aged; Anticoagulants; Blood Glucose; Drug Interactions; Female; Fibrinolytic Agents; Humans; Hypoglycemic Agents; International Normalized Ratio; Male; Metformin; Middle Aged; Phenprocoumon; Registries; Retrospective Studies; Vitamin K; Warfarin | 2016 |
Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Contraceptives, Oral, Combined; Digoxin; Double-Blind Method; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metformin; Thiazoles; Urinary Bladder, Overactive; Warfarin | 2017 |
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclooxygenase 2 Inhibitors; Disease Progression; Docetaxel; Heparin, Low-Molecular-Weight; Humans; Male; Metformin; Models, Theoretical; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Taxoids; Treatment Outcome; Warfarin | 2017 |
Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Humans; Hypoglycemic Agents; Male; Metformin; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Severity of Illness Index; Treatment Outcome; Vascular Calcification; Warfarin | 2018 |
Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Medicaid; Medicare; Metformin; Middle Aged; Sulfonylurea Compounds; United States; Warfarin | 2019 |
Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Self-Controlled Case Series Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Interactions; Female; Hemorrhage; Humans; Hypoglycemic Agents; Male; Medicaid; Metformin; Middle Aged; Risk Assessment; Risk Factors; Sulfonylurea Compounds; United States; Warfarin; Young Adult | 2020 |
Urolithin A Attenuates Diabetes-Associated Cognitive Impairment by Ameliorating Intestinal Barrier Dysfunction via N-glycan Biosynthesis Pathway.
Topics: Animals; Cognitive Dysfunction; Coumarins; Diabetes Mellitus, Type 2; Diet, High-Fat; Inflammation; Intestinal Diseases; Metformin; Mice; Mice, Inbred C57BL; Polysaccharides | 2022 |
Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetes.
Topics: Anticoagulants; Cohort Studies; Diabetes Mellitus, Type 2; Glucose; Humans; International Normalized Ratio; Metformin; Warfarin | 2023 |